Sandostatin LAR and associated names

Procedure started
Under evaluation
CHMP opinion
European Commission final decision

Overview
Key facts
All documents

Current status:

European Commission final decision

Overview

On 26 June 2014, the European Medicines Agency completed a review of Sandostatin LAR. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Sandostatin LAR in the European Union (EU).

: Sandostatin LAR is a medicine that contains the active substance octreotide. Octreotide is a synthetic substance that mimics the activity of the natural hormone somatostatin. Like somatostatin, octreotide blocks the release of hormones found in the body, particularly growth hormone but also others such as thyroid-stimulating hormone (TSH) and various gut hormones. In Sandostatin LAR, octreotide is contained into microspheres that release the octreotide slowly over a few weeks, allowing the medicine to be given once a month.
Sandostatin LAR has been authorised in the EU since the 1990s for treating various conditions, including acromegaly (a disease in which the pituitary gland produces too much growth hormone, leading to excess growth of body tissues and organs) and gastro-entero-pancreatic endocrine tumours (tumours that arise from cells in the gut which release hormones that control various functions of the digestive system).
Sandostatin LAR is available as powder and solvent to be mixed to make a suspension for injection into a muscle. The medicine is marketed in all the EU Member States.
The company that markets these medicines is Novartis.

: Sandostatin LAR is authorised in the EU via national procedures. This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Sandostatin LAR was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).
On 22 May 2013, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Sandostatin LAR in the EU.

The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.

The areas harmonised include:

4.1 Therapeutic indications

After reviewing the available data supporting the medicine's use, the CHMP agreed that Sandostatin LAR should continue to be used for the following conditions:

Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.
Treatment of patients with symptoms associated with functional gastro‑entero‑pancreatic endocrine tumours.
Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.
Treatment of TSH‑secreting pituitary adenomas (benign tumours of the pituitary gland):
- when secretion has not normalised after surgery and/or radiotherapy;
- in patients in whom surgery is inappropriate;
- in patients who have received radiotherapy, until the radiotherapy is effective.

4.2 Posology and method of administration

Having harmonised the indications, the CHMP also harmonised recommendations on the doses and duration of treatment. In addition, the CHMP recommended that Sandostatin LAR be given by deep injection into the gluteal (buttock) muscle.

4.3 Contra-indications

The CHMP agreed that hypersensitivity (allergy) to octreotide or any other ingredients in Sandostatin LAR should be the only contraindication.

Other changes

The CHMP also harmonised other sections of the SmPC including sections 4.4 (special warning and precautions for use), 4.6 (pregnancy and lactation) and 4.8 (side effects).

A European Commission decision on this opinion will be issued in due course.

List item

Questions and answers on Sandostatin LAR and associated names (octreotide, 10, 20 and 30 mg powder and solvent for suspension for injection) (PDF/82.32 KB)

First published: 27/06/2014
Last updated: 27/06/2014
EMA/376450/2014

Key facts

About this medicine
Approved name	Sandostatin LAR and associated names
International non-proprietary name (INN) or common name	ocreotide

About this procedure
Reference number	EMEA/H/A-30/001355
Type	Article 30 referrals This type of referral is triggered when Member States have adopted different decisions over the years for some medicines (e.g. different indications, contraindications or posology) and there is a need to harmonise across the EU.
Status	European Commission final decision

Key dates and outcomes
CHMP opinion date	26/06/2014
EC decision date	26/06/2014

All documents

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

Overview - lay-language summary of the stage of the procedure
Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.

Sandostatin LAR and associated names

Table of contents

Overview

Questions and answers on Sandostatin LAR and associated names (octreotide, 10, 20 and 30 mg powder and solvent for suspension for injection) (PDF/82.32 KB)

Key facts

All documents

Questions and answers on Sandostatin LAR and associated names (octreotide, 10, 20 and 30 mg powder and solvent for suspension for injection) (PDF/82.32 KB)

Sandostatin LAR - Article 30 referral - Annex III (PDF/172.76 KB)

How useful was this page?